摘要:
A catalyst for synthesis reaction that can allow the cross coupling reaction at an improved yield, and yet can be collected after used for the reaction and recycled, and a synthesizing method for a compound using the same catalyst for synthesis reaction. In the Suzuki cross-couplings given by the following reaction formula (15), palladium containing perovskite-like composite oxide is used as a catalyst for synthesis reaction:
摘要:
The invention relates to the use of ABIN2 to stabilise TPL-2, and a ternary complex formed between ABIN2, TPL-2 and p105, as well as assays for compounds capable of modulating the interaction between ABIN2 and TPL-2 and/or p105 and use of such compounds in the treatment of inflammatory conditions.
摘要:
There is provided processes for metal mediated reactions, particularly cross coupling and carbometallation reactions, wherein the metal is present as a catalyst system comprising a catalyst microencapsulated within a permeable polymer microcapsule shell and the reaction is carried out under super-critical or near super-critical conditions. Preferred metal-mediated cross coupling reactions include Heck, Suzuki, Sonogashira and Stille reactions. Preferred carbometallation reactions include hydroformylations.
摘要:
To provide a catalyst for synthesis reaction which can achieve good yield in the Sonogashira reaction and also can be recovered after the reaction, and a method for synthesizing a compound in which the catalyst for synthesis reaction is used, a perovskite-type composite oxide containing palladium is used as the catalyst for synthesis reaction in the Sonogashira reaction represented by the following reaction scheme (1): R1—X+HC≡CR2→R1C≡CR2 (1)
摘要翻译:为了提供合成反应的催化剂,其能够在Sonogashira反应中获得良好的产率,并且也可以在反应后回收,以及合成其中使用合成反应的催化剂的化合物的方法,含有钯的钙钛矿型复合氧化物 用作由以下反应方案(1)表示的Sonogashira反应中的合成反应的催化剂:<?in-line-formula description =“In-line formula”end =“lead”?> R&lt; 1& / SUB + -X +HC≡CR2 - > R 1C≡CR2(1)<β在线公式描述 =“内联公式”end =“tail”?>
摘要:
An agent for use in medicine, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of C-reactive protein (CRP) molecules in the presence thereof, wherein (i) at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the CRP molecules; or (ii) at least one of the ligands is capable of being bound by a ligand binding site present on a CRP molecule, and at least one other of the ligands is capable of being bound by a ligand binding site present on a serum amyloid P component (SAP) molecule.